Key Drivers
- Narrower Losses
- Improved Liquidity
- Persistent Dilution
AIAI Summary
SOPH's 27% growth and AstraZeneca partnership are promising, but the investment case remains a high-risk execution bet until gross margins stabilize, cash burn narrows toward breakeven, and biopharma revenue materializes without further dilution—making disciplined entry after momentum cools preferable.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Narrower Losses
- •Improved Liquidity
- •Persistent Dilution
SOPH's liquidity, leverage, losses, and cash burn improved, but persistent unprofitability, dilution, accumulated deficits, and a premium valuation keep the investment case high-risk.
Price Behavior
Key Price Behavior Insights:
- •Higher Highs
- •Rapid Acceleration
- •Pullback Risk
SOPH's strong 51% last-month rally shows bullish higher highs, but its RSI near 82 signals overbought conditions and elevated pullback risk below $7.50–$7.62.
Sharp rise from $6.30 to above $8.00 highlights elevated short-term volatility
Sentiment & News
Key News Insights:
- •Guidance raised
- •AstraZeneca collaboration
- •Margin pressure
SOPHiA GENETICS raised 2026 guidance on strong growth and AstraZeneca momentum, though declining margins remain a concern.
The news is moderately positive for SOPHiA GENETICS' stock, with stronger growth offset by profitability concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings